Cardiology Division of Internal Medicine Department, South Valley University Hospital, Faculty of Medicine, South Valley University, Qena, 83523, Egypt.
Department of Medical Biochemistry, Faculty of Medicine, South Valley University, Qena, 83523, Egypt.
Vasc Health Risk Manag. 2023 Jul 6;19:411-420. doi: 10.2147/VHRM.S416206. eCollection 2023.
The prognostic role of the soluble circulating suppression of tumorigenicity 2 marker (sST2) in different cardiovascular diseases (CVD) is still under investigation. This research aimed to assess the serum levels of sST2 in the blood of individuals with ischemic heart disease and its relation to disease severity, also to examine any changes in sST2 levels following a successful percutaneous coronary intervention (PCI) in those patients.
A total of 33 ischemic patients and 30 non-ischemic controls were included. The plasma level of sST2 was measured using commercially available ELISA assay kit, at baseline and 24-48 h after the intervention in the ischemic group.
On admission, there was a significant difference between the group of acute/chronic coronary syndrome cases and controls regarding the sST2 plasma level (p < 0.001). There was an insignificant difference between the three ischemic subgroups at the baseline sST2 level (p = 0.38). The plasma sST2 level decreased significantly after PCI (from 20.70 ± 1.71 to 16.51 ± 2.43, p = 0.006). There was a modestly just significant positive correlation between the acute change in post-PCI sST2 level and the severity of ischemia as measured by the Modified Gensini Score (MGS) (r = 0.45, p = 0.05). In spite of the highly significant improvement in the coronary TIMI flow of ischemic group after PCI, there was insignificant negative correlation between the post- PCI delta change in the sST2 level and the post-PCI TIMI coronary flow grade.
A significantly high plasma level of sST2 in patients with myocardial ischemia and controlled cardiovascular risk factors showed an immediate reduction after successful revascularization. The high baseline level of the sST2 marker and the acute post-PCI reduction was mainly related to the severity of ischemia rather than left ventricular function.
可溶性循环肿瘤抑制物 2 标志物（sST2）在不同心血管疾病（CVD）中的预后作用仍在研究中。本研究旨在评估缺血性心脏病患者血液中 sST2 的血清水平及其与疾病严重程度的关系，并观察这些患者经皮冠状动脉介入治疗（PCI）后 sST2 水平的变化。
共纳入 33 例缺血性患者和 30 例非缺血性对照者。使用商业上可获得的 ELISA 试剂盒在基线和缺血组介入后 24-48 小时测量 sST2 的血浆水平。
入院时，急性/慢性冠状动脉综合征组与对照组之间的 sST2 血浆水平存在显著差异（p<0.001）。在基线 sST2 水平上，三个缺血亚组之间无显著性差异（p=0.38）。PCI 后 sST2 水平显著降低（从 20.70±1.71 降至 16.51±2.43，p=0.006）。PCI 后 sST2 水平的急性变化与改良 Gensini 评分（MGS）测量的缺血严重程度呈适度正相关（r=0.45，p=0.05）。尽管缺血组经 PCI 后冠状动脉 TIMI 血流有显著改善，但 PCI 后 sST2 水平的变化与 PCI 后 TIMI 冠状动脉血流分级之间无显著负相关。
心肌缺血患者的血浆 sST2 水平显著升高，且控制心血管危险因素，经成功血运重建后即刻降低。sST2 标志物的高基线水平和 PCI 后的急性降低主要与缺血严重程度有关，而与左心室功能无关。
